LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡

Core Insights - LifeVantage Corporation announced new results from its second human clinical study on the MindBody GLP-1 System™, showing significant improvements in GLP-1 levels and related health outcomes [1][2] Clinical Study Results - The average increase in GLP-1 production improved to over 200%, up from a previously reported 140% [2] - Participants experienced an average weight loss of 11 pounds within 12 weeks, with some losing up to 25 pounds [6] - There was a reported decrease in total body fat percentage of up to 9% and a decrease in visceral fat of up to 24% [6] - Participants reported a 100% weight loss from fat, not muscle, and a 6% increase in skeletal muscle [6] Behavioral Changes - 95% of participants reported decreased sugar cravings, while 89% reported decreased fast-food cravings [6] - 85% of participants indicated they now eat for health instead of emotions, and 81% reported an increased ability to resist snacking [6] - 89% of participants ate less at meals, and 86% reported feeling less hungry [6] Company Background - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [5] - The company offers a range of products, including the MindBody GLP-1 System™, aimed at promoting optimal health at the cellular level [5]